Date Log
Submitted
November 17, 2021
Published
November 17, 2021
Short introduction of sublingual drug delivery system
Corresponding Author(s) : Asha Kumari
ashamahtoa@gmail.com
International Journal of Allied Medical Sciences and Clinical Research,
Vol. 2021 No. 9 (4): 2021 Volume - 9 Issue - 4
Abstract
Onset of action is needed in the case of some acute diseases. Hence the Sublingual drug delivery can be best promising route of administration for a faster and direct absorption of drug into systemic circulation. The most permeable region for a drug absorption in buccal cavity is the Sublingual region. Absorption of a drug through the sublingual blood vessels bypasses the hepatic first-pass metabolism that makes better bioavailability along good patient compliance. Such sublingual approaches present numerous pharmaceutical and patient needs those are enhanced life-cycle management to suitable dosing for children as well as elderly along psychiatric patients with dysphagia. This review is to give a brief and complete overview of sublingual technologies along new and old approaches.
Keywords
Sublingual
permeability
bioavailability
first pass metabolism
dysphagia
Dr. Mayank Bansal, Jitendra Kumar, Sunil Sain, & Asha Kumari. (2021). Short introduction of sublingual drug delivery system. International Journal of Allied Medical Sciences and Clinical Research, 2021(9), 652–656. https://doi.org/10.61096/ijamscr.v2021.iss9.4.652-656
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX
References
-
1. Aburahma MH, El-Laithy HM, Hamza YE. Preparation and In Vitro/ In Vivo Characteriza- tion of porous sublingual tablets containing ternary kneaded solid system of Vinpocetine with ?-Cyclodextrin and hydroxy acid. Sci Pharm. 2010; 78; 363-379.
2. Al-Ghananeem AM, Malkawi AH, Crooks PA. Scopolamine sublingual spray: an alternative route of delivery for the treatment of motion sickness. Drug Dev Ind Pharm. 2007; 33(5): 577–582.
3. Boer D, et al. Drug absorption by sublingual and rectal routes. Brit J Anaesth. 1984; 56: 69-82.
4. Bolourtchian N, Hadidi N, Foroutan SM, Sha- faghi B. Development and optimization of sub- lingual tablet formulation for Physostigmine Salicylate. Acta Pharm. 2009; 59: 301-312.
5. Bolourtchian N, Hadidi N, Foroutan SM, Sha- faghi B. Formulation and optimization of cap- topril sublingual tablet using D-Optimal de- sign. Iranian J Pharm Res. 2008; 7(4): 259-267.
6. Bottenbrg P, Cleymact R, dc Muynck C, Rey- mon JP, Coomans D, Michotte Y, et al. Devel- opment and testing of fluoride containing slow release tablets for oral use. J Pharm Pharmacol. 1991; 43: 457-464.
7. Centkowska K, Sznitowska M. Comparison of sublingual tablets with nitroglycerin com- plexed with ?-Cyclodextrin or titrated with crosspovidone - Technological approach. Acta Pol Pharm- Drug Res. 2008; 65(5): 585-589.
8. Ghosh TK, Chatterjee DJ, Pfister WR. Quick dissolving oral dosage forms: Scientific and regulatory considerations from a clinical Pharmacology and Biopharmaceutical perspective, In: Ghosh TK, Pfister WR, editors, Drug Delivery to the Oral Cavity Molecules to Market, NY, USA; CRC Press: 3537-3567 (2005).
9. Haegeli L, Brunner-La Rocca HP, Wenk M, Pfisterer M, Drewe J, Krahenbuhl S. Sublingual administration of furosemide: new application of an old drug. Brit J Clin Pharmcol. 2007; 64(6): 804-809.
10. John DN, Fort S, Lewis MJ, Luscombe DK. Pharmacokinetics and Pharmacodynamics of Verapamil following sublingual and oral ad- ministration to healthy volunteers. Br J Clin Pham 1992; 33: 623-627.
11. Kurosaki Y, Takatori T, Nishimura H, Na- kayama T, Kimura T. Regional variation in oral mucosal drug absorption permeability and degree of keratinization in hamster oral cavity. Pharm Res. 1991; 8: 1297-1301.
12. Lipinski CA, Lombardo F, Dominy BW, Fee- ney PJ. Experimental and computational approaches to estimate solubility and permeabili- ty in drug discovery and development set- tings. Adv Drug Del Rev. 1997; 23: 3-25.
13. McElnay JC, Al-Furaih TA, Hughes CM, Scott MG, Elborn JS, Nicholls DP. The effect of pH on the buccal and sublingual absorption of captopril. Eur J Clin Pharmacol. 1995; 48(5): 373-379.
14. Nafee NA, Boraie NA, Ismail FA, Mortada IM. Design and characterization of mucoadhesive buccal patches containing cetylpyridinium chloride. Acta Pharm. 2003; 53: 199-212.
15. Narang N, Sharma J. Sublingual mucosa as a route for systemic drug delivery. Int J Pharm Pharm Sci. 2011; 3(2): 18-22.
16. Peh KK, Wong CF. Polymeric films as vehicles for buccal delivery; swelling, mechanical, and films of glipizide. Indian J Pharm Sci. 2008; 70:43-48.
17. Price TM, Blauer KL, Hansen M, Stanczyk F, Lobo R, Bates GW. Single - dose Pharmacoki- netics of sublingual versus oral administration of micronized 17 beta – estradiol. Obstet Gyne- col. 1997; 89: 340-345.
18. Richman MD, Fox D, Shangraw RF. Prepara- tion and stability of glyceryl trinitrate sublin- gual tablets prepared by direct compression. J Pharm Sci. 1965; 54(3): 447-451.
19. Shojaie AH. Buccal mucosa as a route for sys- temic drug delivery: A review. J Pharm Pharm Sci. 1998; 1(1): 15-30.
20. Sheeba FR, Acharya GD, Rameshwari S, Jeya AJ. Formulation and evaluation of nifedipine sublingual tablets. Asian J Pharm Clin Res. 2009; 2(3): 44-48.
21. Thosar M M. Intra oral sprays -An overview. Int J Pharm Life Sci. 2011; 2(11):1235-1246.
22. Walton RP. Absorption of drugs through the oral mucosa III Fat -water solubility co- efficient of alkaloids. Proc Soc Exp Bio Med. 1935; 32: 1488-1493.
References
1. Aburahma MH, El-Laithy HM, Hamza YE. Preparation and In Vitro/ In Vivo Characteriza- tion of porous sublingual tablets containing ternary kneaded solid system of Vinpocetine with ?-Cyclodextrin and hydroxy acid. Sci Pharm. 2010; 78; 363-379.
2. Al-Ghananeem AM, Malkawi AH, Crooks PA. Scopolamine sublingual spray: an alternative route of delivery for the treatment of motion sickness. Drug Dev Ind Pharm. 2007; 33(5): 577–582.
3. Boer D, et al. Drug absorption by sublingual and rectal routes. Brit J Anaesth. 1984; 56: 69-82.
4. Bolourtchian N, Hadidi N, Foroutan SM, Sha- faghi B. Development and optimization of sub- lingual tablet formulation for Physostigmine Salicylate. Acta Pharm. 2009; 59: 301-312.
5. Bolourtchian N, Hadidi N, Foroutan SM, Sha- faghi B. Formulation and optimization of cap- topril sublingual tablet using D-Optimal de- sign. Iranian J Pharm Res. 2008; 7(4): 259-267.
6. Bottenbrg P, Cleymact R, dc Muynck C, Rey- mon JP, Coomans D, Michotte Y, et al. Devel- opment and testing of fluoride containing slow release tablets for oral use. J Pharm Pharmacol. 1991; 43: 457-464.
7. Centkowska K, Sznitowska M. Comparison of sublingual tablets with nitroglycerin com- plexed with ?-Cyclodextrin or titrated with crosspovidone - Technological approach. Acta Pol Pharm- Drug Res. 2008; 65(5): 585-589.
8. Ghosh TK, Chatterjee DJ, Pfister WR. Quick dissolving oral dosage forms: Scientific and regulatory considerations from a clinical Pharmacology and Biopharmaceutical perspective, In: Ghosh TK, Pfister WR, editors, Drug Delivery to the Oral Cavity Molecules to Market, NY, USA; CRC Press: 3537-3567 (2005).
9. Haegeli L, Brunner-La Rocca HP, Wenk M, Pfisterer M, Drewe J, Krahenbuhl S. Sublingual administration of furosemide: new application of an old drug. Brit J Clin Pharmcol. 2007; 64(6): 804-809.
10. John DN, Fort S, Lewis MJ, Luscombe DK. Pharmacokinetics and Pharmacodynamics of Verapamil following sublingual and oral ad- ministration to healthy volunteers. Br J Clin Pham 1992; 33: 623-627.
11. Kurosaki Y, Takatori T, Nishimura H, Na- kayama T, Kimura T. Regional variation in oral mucosal drug absorption permeability and degree of keratinization in hamster oral cavity. Pharm Res. 1991; 8: 1297-1301.
12. Lipinski CA, Lombardo F, Dominy BW, Fee- ney PJ. Experimental and computational approaches to estimate solubility and permeabili- ty in drug discovery and development set- tings. Adv Drug Del Rev. 1997; 23: 3-25.
13. McElnay JC, Al-Furaih TA, Hughes CM, Scott MG, Elborn JS, Nicholls DP. The effect of pH on the buccal and sublingual absorption of captopril. Eur J Clin Pharmacol. 1995; 48(5): 373-379.
14. Nafee NA, Boraie NA, Ismail FA, Mortada IM. Design and characterization of mucoadhesive buccal patches containing cetylpyridinium chloride. Acta Pharm. 2003; 53: 199-212.
15. Narang N, Sharma J. Sublingual mucosa as a route for systemic drug delivery. Int J Pharm Pharm Sci. 2011; 3(2): 18-22.
16. Peh KK, Wong CF. Polymeric films as vehicles for buccal delivery; swelling, mechanical, and films of glipizide. Indian J Pharm Sci. 2008; 70:43-48.
17. Price TM, Blauer KL, Hansen M, Stanczyk F, Lobo R, Bates GW. Single - dose Pharmacoki- netics of sublingual versus oral administration of micronized 17 beta – estradiol. Obstet Gyne- col. 1997; 89: 340-345.
18. Richman MD, Fox D, Shangraw RF. Prepara- tion and stability of glyceryl trinitrate sublin- gual tablets prepared by direct compression. J Pharm Sci. 1965; 54(3): 447-451.
19. Shojaie AH. Buccal mucosa as a route for sys- temic drug delivery: A review. J Pharm Pharm Sci. 1998; 1(1): 15-30.
20. Sheeba FR, Acharya GD, Rameshwari S, Jeya AJ. Formulation and evaluation of nifedipine sublingual tablets. Asian J Pharm Clin Res. 2009; 2(3): 44-48.
21. Thosar M M. Intra oral sprays -An overview. Int J Pharm Life Sci. 2011; 2(11):1235-1246.
22. Walton RP. Absorption of drugs through the oral mucosa III Fat -water solubility co- efficient of alkaloids. Proc Soc Exp Bio Med. 1935; 32: 1488-1493.
2. Al-Ghananeem AM, Malkawi AH, Crooks PA. Scopolamine sublingual spray: an alternative route of delivery for the treatment of motion sickness. Drug Dev Ind Pharm. 2007; 33(5): 577–582.
3. Boer D, et al. Drug absorption by sublingual and rectal routes. Brit J Anaesth. 1984; 56: 69-82.
4. Bolourtchian N, Hadidi N, Foroutan SM, Sha- faghi B. Development and optimization of sub- lingual tablet formulation for Physostigmine Salicylate. Acta Pharm. 2009; 59: 301-312.
5. Bolourtchian N, Hadidi N, Foroutan SM, Sha- faghi B. Formulation and optimization of cap- topril sublingual tablet using D-Optimal de- sign. Iranian J Pharm Res. 2008; 7(4): 259-267.
6. Bottenbrg P, Cleymact R, dc Muynck C, Rey- mon JP, Coomans D, Michotte Y, et al. Devel- opment and testing of fluoride containing slow release tablets for oral use. J Pharm Pharmacol. 1991; 43: 457-464.
7. Centkowska K, Sznitowska M. Comparison of sublingual tablets with nitroglycerin com- plexed with ?-Cyclodextrin or titrated with crosspovidone - Technological approach. Acta Pol Pharm- Drug Res. 2008; 65(5): 585-589.
8. Ghosh TK, Chatterjee DJ, Pfister WR. Quick dissolving oral dosage forms: Scientific and regulatory considerations from a clinical Pharmacology and Biopharmaceutical perspective, In: Ghosh TK, Pfister WR, editors, Drug Delivery to the Oral Cavity Molecules to Market, NY, USA; CRC Press: 3537-3567 (2005).
9. Haegeli L, Brunner-La Rocca HP, Wenk M, Pfisterer M, Drewe J, Krahenbuhl S. Sublingual administration of furosemide: new application of an old drug. Brit J Clin Pharmcol. 2007; 64(6): 804-809.
10. John DN, Fort S, Lewis MJ, Luscombe DK. Pharmacokinetics and Pharmacodynamics of Verapamil following sublingual and oral ad- ministration to healthy volunteers. Br J Clin Pham 1992; 33: 623-627.
11. Kurosaki Y, Takatori T, Nishimura H, Na- kayama T, Kimura T. Regional variation in oral mucosal drug absorption permeability and degree of keratinization in hamster oral cavity. Pharm Res. 1991; 8: 1297-1301.
12. Lipinski CA, Lombardo F, Dominy BW, Fee- ney PJ. Experimental and computational approaches to estimate solubility and permeabili- ty in drug discovery and development set- tings. Adv Drug Del Rev. 1997; 23: 3-25.
13. McElnay JC, Al-Furaih TA, Hughes CM, Scott MG, Elborn JS, Nicholls DP. The effect of pH on the buccal and sublingual absorption of captopril. Eur J Clin Pharmacol. 1995; 48(5): 373-379.
14. Nafee NA, Boraie NA, Ismail FA, Mortada IM. Design and characterization of mucoadhesive buccal patches containing cetylpyridinium chloride. Acta Pharm. 2003; 53: 199-212.
15. Narang N, Sharma J. Sublingual mucosa as a route for systemic drug delivery. Int J Pharm Pharm Sci. 2011; 3(2): 18-22.
16. Peh KK, Wong CF. Polymeric films as vehicles for buccal delivery; swelling, mechanical, and films of glipizide. Indian J Pharm Sci. 2008; 70:43-48.
17. Price TM, Blauer KL, Hansen M, Stanczyk F, Lobo R, Bates GW. Single - dose Pharmacoki- netics of sublingual versus oral administration of micronized 17 beta – estradiol. Obstet Gyne- col. 1997; 89: 340-345.
18. Richman MD, Fox D, Shangraw RF. Prepara- tion and stability of glyceryl trinitrate sublin- gual tablets prepared by direct compression. J Pharm Sci. 1965; 54(3): 447-451.
19. Shojaie AH. Buccal mucosa as a route for sys- temic drug delivery: A review. J Pharm Pharm Sci. 1998; 1(1): 15-30.
20. Sheeba FR, Acharya GD, Rameshwari S, Jeya AJ. Formulation and evaluation of nifedipine sublingual tablets. Asian J Pharm Clin Res. 2009; 2(3): 44-48.
21. Thosar M M. Intra oral sprays -An overview. Int J Pharm Life Sci. 2011; 2(11):1235-1246.
22. Walton RP. Absorption of drugs through the oral mucosa III Fat -water solubility co- efficient of alkaloids. Proc Soc Exp Bio Med. 1935; 32: 1488-1493.
